Short Interest in Tharimmune, Inc. (NASDAQ:THAR) Expands By 113.2%

Tharimmune, Inc. (NASDAQ:THAR) saw a large growth in short interest in March. As of March 31st, there was short interest totalling 64,400 shares, a growth of 113.2% from the March 15th total of 30,200 shares. Based on an average daily volume of 85,200 shares, the days-to-cover ratio is presently 0.8 days. Currently, 3.1% of the shares of the company are sold short.

Tharimmune Trading Down 4.3 %

THAR opened at $1.10 on Thursday. The stock’s 50 day simple moving average is $1.47 and its 200-day simple moving average is $1.94. The stock has a market cap of $2.32 million, a PE ratio of -0.11 and a beta of 1.18. Tharimmune has a 1 year low of $0.95 and a 1 year high of $6.45.

Tharimmune (NASDAQ:THAR) last announced its quarterly earnings data on Tuesday, March 25th. The company reported ($2.02) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Tharimmune stock. Virtu Financial LLC bought a new position in Tharimmune, Inc. (NASDAQ:THAR) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 21,371 shares of the company’s stock, valued at approximately $44,000. Virtu Financial LLC owned approximately 1.11% of Tharimmune at the end of the most recent quarter. 1.16% of the stock is owned by institutional investors.

Tharimmune Company Profile

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).